The introduction of high-quality, standardised immunotherapy extracts has reinforced the interest in treating the high prevalence disease-
Childhood allergic asthma. Other clinical trials have also been carried out with many systematic reviews and meta-analyses that overall indicate that allergen immunotherapy in paediatric asthma has a clinical effectiveness. New data have also been released on the preventive impact of treatment on asthma. Nevertheless, numerous fascinating questions arose in conjunction with knowledge creation.
The overall successful allergic immunotherapy is asthma therapy for children; however, the effectiveness of each individual product should not be asserted for a class effect. The new findings show that the future research challenge will be clarifying the extent of the preventive impact and the optimum period of therapy: when to begin immunotherapy in children, which are (if available) the predictive biomarkers for efficacy in the person.
